timothy sykes logo
Moderna Stock Falls 5% As Recent Retreat Continues Thumbnail

Moderna Stock Falls 5% As Recent Retreat Continues

TIMOTHY SYKES•UPDATED NOV. 18, 2026, 9:55 AM ET

Moderna fell 5% despite encouraging plans to seek approval for its personalized cancer treatment.

MRNA Candlestick Chart

Why Moderna Stock Is Falling Today

Moderna (NASDAQ: MRNA) last traded at $195.70, down 5% from $206.80, in trading after the regular market session closed. No company news or filing was found to explain the decline.

Moderna Shares Retreat After Early High

Shares reached a high near $210 in premarket trading, meaning trading before the regular session opened. Trading totaled about 6.9 million shares and was light, rather than evidence of unusually heavy selling.

Moderna Cancer Treatment Filing Plans

Moderna and Merck, the drugmaker partnering on its cancer treatment, plan a U.S. application for Intismeran following positive final-stage trial results. The treatment is tailored to features of each patient’s tumor and was studied in melanoma, a form of skin cancer. The application requests permission to market the treatment; submitting it does not grant approval or start sales.

Moderna Falls Despite Favorable Cancer Update

The favorable filing outlook did not stop the decline. One possible explanation is that investors had already paid for that progress through the stock’s earlier gains.

Moderna Industry Forecast Is Not Revenue

A separate industry report projects a $44.04 billion market this year for products used against public health emergencies. That forecast does not represent a Moderna contract or company sales.

Quick Financial Overview

Moderna is profitable and a large-cap, a large company with a total stock market value of $79.18B. Its $5.17B in cash, cash equivalents, and short-term investments as of September 30, 2026 includes money on hand and investments readily turned into cash. That covers about ten months if the latest spending pace continues.

Moderna Revenue and Quarterly Earnings

The latest quarter produced revenue of $1.31B, with net income of $162.0M, meaning profit after expenses. Those results describe the existing business, rather than sales from the unapproved cancer treatment.

Moderna Profit and Cash Spending

Business operations consumed $1.56B during the same quarter, meaning cash left the business despite its reported profit. Accounting earnings and cash movement measure different things, so a profitable quarter does not necessarily replenish available funds. The cash estimate assumes unchanged spending, rather than predicting an exact date when funds run out.

Moderna Stock Retreats From Last Month

Moderna has retreated from the $240 level over the past month, extending a run of lower prices. For perspective, the last daily move this large was four sessions ago, so today’s decline is not isolated.

Moderna Cancer Treatment Manufacturing Readiness

Management describes Moderna as ready to supply the treatment commercially, but it remains unapproved. Manufacturing readiness could help turn a future approval into sales. Regulatory review still stands between the development program and that business opportunity.

Conclusion

The next dated checkpoint is the expected U.S. application by year-end. Meeting that timetable would show Moderna can execute its development plans, while a delay would push the next step back. Under the current spending assumption, Moderna has to raise more money, although no financing has been announced.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:


How much has this post helped you?



Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”